Picture of Nick Beckett

Nick Beckett

Managing Partner
Managing Partner, Beijing Office, Global Co-Head of Lifesciences

CMS Cameron McKenna Nabarro Olswang LLP
Cannon Place
78 Cannon Street
London
EC4N 6AF
United Kingdom
CMS China
Beijing Representative Office
Room 1909, China Youth Plaza
No. 19 Dongsanhuan North Road
Chaoyang District, Beijing 100026
China
Languages English, French
Dispute Resolution

Nick Beckett is the Managing Partner of the Beijing Office, Global Co-Head of Lifesciences and Head of Asia-Pacific IP.  Nick manages a team of dedicated sector specialists covering Lifesciences, Energy, TMC and Financial Institutions across the Asia-Pacific region. 

He has extensive experience in dispute resolution, particularly intellectual property and in the Lifesciences and TMC sectors.  Nick’s practice has involved coordinating complex multi-jurisdictional matters in the areas of commercial and corporate disputes, parallel trade, anti-counterfeiting and trade mark and patent litigation.

more less

Heavyweight IP, parallel trade and patent litigation capability for an impressive roster of clients.

Legal 500

Nick is recommended as a prominent practitioner in his field in the Global Law Experts 2015 for China, PLC Lifesciences Handbook, Super Lawyers London and the Guide to the World’s Leading Trade Mark Law Practitioners.

Relevant experience

  • One of the world’s leading information technology services companies and successfully defending it in China against a top Chinese state-owned enterprise and its subsidiaries in respect of a management consultancy project and an ERP project that our client implemented for them under a global strategic framework agreement.
  • A world-leading supplier of edible coatings to the pharmaceuticals industry in connection with a patent infringement matter spanning a number of jurisdictions, including China.
  • A leading global bed specialist on the highly sensitive and important employment termination of its former management team in China, including its Managing Director and two senior sales leaders based on unsatisfactory performance and serious wrongdoings.
  • Erbe in the first ever UK patent litigation to deal separately with the issues of infringement and validity coordinating with equivalent litigation in Germany, the US and before the EPO.
  • A Japanese pharmaceutical company in a very significant ICC arbitration, with damages of up to $1 billion, concerning a dispute under a worldwide patent licence agreement in the pharmaceutical sector as a result of the wrongful withdrawal of a licensed pharmaceutical product from the market without consent.
  • Asahi Medical in patent litigation in the UK Patents Court and Court of Appeal for a large Japanese medical device company in connection with their blood filtration technology. This also entailed coordinating concurrent litigation across Europe and liaising with the client's Japanese and European patent attorneys.
  • A leading global pharmaceutical company in a high profile dispute concerning a blockbuster pharmaceutical product. The dispute entailed coordinating litigation in Japan and the UK and jurisdictional issues. Complex pharmaceutical litigation, as well as complicated questions of contract law arose.
  • Takeda on successfully opposing the grant of a competitor’s (Bethesda Pharmaceuticals Inc) European patent at the Opposition Division of the European Patent Office.
  • Quinn Group in connection with a branding dispute regarding the rebranding of the Belfry Hotel as part of the De Vere hotel chain.
  • Sports World International in numerous trade mark litigation matters relating to its own and licensed brands including Kangol, Diadora, Puma and Lonsdale.
more less

Education

2005 - Advocacy Diploma, The College of Law, London

2000 - Intellectual Property Diploma, Bristol University, Bristol

1996 - LPC Distinction, The College of Law, London

1996 - Professional Skills Course, BPP, London

1995 - CPE Distinction, Manchester Metropolitan University, Manchester

1994 - BSc Hons Psychology 1st, University of Manchester, Manchester

more less

Memberships

Honorary Lecturer - China Pharmaceutical University, Nanjing, China

Lecturer - Peking University, China

Lecturer - University of International Business and Economics (UIBE) 

Lecturer - China-EU School of Law, China University of Political Science and Law

more less
Intellectual Property

Nick Beckett is the Managing Partner of the Beijing Office, Global Co-Head of Lifesciences and Head of Asia-Pacific IP. Nick manages a team of dedicated sector specialists covering Lifesciences, Energy, TMC and Financial Institutions across the Asia-Pacific region.

Nick has extensive experience in advising on all aspects of intellectual property and commercial matters affecting a wide range of international clients, particularly in the Lifesciences and TMC sectors.  Nick’s practice spans both contentious and non-contentious issues and has involved coordinating complex multi-jurisdictional matters in the areas of commercial and corporate transactions and disputes, parallel trade, anti-counterfeiting, due diligence and trade mark and patent opinions. 

more less

Heavyweight IP, parallel trade and patent litigation capability for an impressive roster of clients.

Legal 500

Nick is recommended as a prominent practitioner in his field in the Global Law Experts 2015 for China, PLC Lifesciences Handbook, Super Lawyers London and the Guide to the World’s Leading Trade Mark Law Practitioners.

Relevant experience

  • A European automotive manufacturer in its IP licensing and actions to protect its portfolio from alleged infringement in many jurisdictions by several companies, including China.
  • Erbe in the first ever UK patent litigation to deal separately with the issues of infringement and validity coordinating with equivalent litigation in Germany, the US and before the EPO.
  • A world leading IT network company on the coordination of enforcement activity against a Chinese trademark infringer.
  • A leading international agrochemical company for the client's Crop Protection Business on patent infringement, anti-counterfeiting, customs and regulatory dispute work, including coordinating with other CMS offices and bringing together a network to service the client's needs.
  • An art tools manufacturer on the strategic restructuring of its trademark portfolio in China and the implementation of further agreements to bolster the value of its rights.
  • A world-leading supplier of edible coatings to the pharmaceuticals industry in connection with a patent infringement matter spanning a number of jurisdictions. This involved coordinating patent litigation and patent prosecution, as well as advising the client on general commercial strategy.
  • A Hong Kong based biotechnology company on a freedom to operate (FTO) search on a number of its core products across Asia-Pacific.
  • BudejovickyMetanskyPivovar in trade mark litigation with Anheuser- Busch relating to use of the term BUDWEISER.
  • A major US pharmaceutical company in disputes with numerous parallel traders.
  • Quinn Group in connection with a branding dispute regarding the rebranding of the Belfry Hotel as part of the De Vere hotel chain.
more less

Education

2005 - Advocacy Diploma, The College of Law, London

2000 - Intellectual Property Diploma, Bristol University, Bristol

1996 - LPC Distinction, The College of Law, London

1996 - Professional Skills Course, BPP, London

1995 - CPE Distinction, Manchester Metropolitan University, Manchester

1994 - BSc Hons Psychology 1st, University of Manchester, Manchester

more less

Memberships

Honorary Lecturer - China Pharmaceutical University, Nanjing, China

Lecturer - Peking University, China

Lecturer - University of International Business and Economics (UIBE) 

Lecturer - China-EU School of Law, China University of Political Science and Law

more less
Lifesciences & Healthcare

Nick Beckett is the Managing Partner of the Beijing Office, Global Co-Head of Lifesciences and Head of Asia-Pacific IP.  Nick manages a team of dedicated sector specialists covering Lifesciences, Energy, TMC and Financial Institutions across the Asia-Pacific region.

Nick has extensive experience in advising on all aspects of intellectual property and commercial matters affecting a wide range of international clients, particularly in the Lifesciences sector.  His practice spans both contentious and non-contentious issues and has involved coordinating complex multi-jurisdictional matters in the areas of commercial and corporate transactions and disputes, parallel trade, anti-counterfeiting, due diligence and trade mark and patent opinions. 

more less

Heavyweight IP, parallel trade and patent litigation capability for an impressive roster of clients.

Legal 500

Nick is recommended as a prominent practitioner in his field in the Global Law Experts 2015 for China, PLC Lifesciences Handbook, Super Lawyers London and the Guide to the World’s Leading Trade Mark Law Practitioners.

Relevant experience

  • Takeda Pharmaceutical Company Limited on its €9.6 billion (debt-free cash free) acquisition of Swiss drug company, Nycomed A/S.
  • A Japanese pharmaceutical company in a very significant ICC arbitration, with damages of up to $1 billion, concerning a dispute under a worldwide patent licence agreement in the pharmaceutical sector as a result of the wrongful withdrawal of a licensed pharmaceutical product from the market without consent.
  • A global pharmaceutical company on its market entry into China including obtaining relevant licence and setting up a compliance program, establishing its branch company in China and preparing and submitting the legal documents for the registration with the local authorities.
  • A world leading gas supplier on its joint medical institution project in China in cooperation with its domestic partner from various perspectives (corporate, compliance, regulatory and commercial).
  • A leading global pharmaceutical company in a high profile dispute concerning a blockbuster pharmaceutical product. The dispute entailed coordinating litigation in Japan and the UK and jurisdictional issues. Complex pharmaceutical litigation, as well as complicated questions of contract law arose.
  • One of the leading traditional Chinese medicine (TCM) companies in China in its management control dispute relating to a joint venture in The Netherlands.
  • Eli Lilly in a leading pharmaceutical parallel trade repackaging case before the CJEU.
  • A global leading medical device company on a strategically important investigation into a compliance breach within their distribution channels in Indonesia and South-East Asia.
  • A Japanese pharmaceutical company on conducting IP due diligence in respect of 2 anti-depressant compounds the subject of a successful world-wide collaboration agreement.
  • A Tianjin-based biotechnology company specialising in novel HIV biologics on international pre-clinical through to Phase III clinical trial development.  Identifying opportunities and facilitating introductions to potential R&D partners in Europe and North America.  Advising on potential entry into Western pharmaceutical markets and the feasibility of deal structures, including the licensing of intellectual property and establishing joint ventures.
more less

Education

2005 - Advocacy Diploma, The College of Law, London

2000 - Intellectual Property Diploma, Bristol University, Bristol

1996 - LPC Distinction, The College of Law, London

1996 - Professional Skills Course, BPP, London

1995 - CPE Distinction, Manchester Metropolitan University, Manchester

1994 - BSc Hons Psychology 1st, University of Manchester, Manchester

more less

Memberships

Honorary Lecturer - China Pharmaceutical University, Nanjing, China

Lecturer - Peking University, China

Lecturer - University of International Business and Economics (UIBE) 

Lecturer - China-EU School of Law, China University of Political Science and Law

more less

Feed

Show only
15/12/2015
CMS Glob­al Lifes­ci­ences For­um 2015
Shap­ing the fu­ture through in­nov­a­tion and col­lab­or­a­tion
28/06/2017
China pub­lishes the Na­tion­al Cy­ber­se­cur­ity In­cid­ent Re­sponse Plan
The Cy­ber­space Ad­min­is­tra­tion of China (“CAC”) pub­lished the Na­tion­al Cy­ber In­cid­ent Re­sponse Plan (the “Plan”) on 27 June 2017. The Plan is for­mu­lated in ac­cord­ance with the gen­er­al prin­ciples of the PRC Cy­ber­se­cur­ity Law.
03/06/2014
Won­der and Danger: Asi­an Leg­al Busi­ness - May 2014
20/06/2017
The China Food and Drug Ad­min­is­tra­tion has is­sued for pub­lic com­ment...
The China Food and Drug Ad­min­is­tra­tion (the “CF­DA”) has is­sued four draft policies en­cour­aging the in­nov­a­tion of drugs and med­ic­al devices (the "Policies”). The Policies aim to im­prove the policy en­vir­on­ment for the re­search and de­vel­op­ment of new drugs and.
01/05/2014
The An­ti­dote - Spring 2014
Tak­ing a look at "pharm­er­ging" mar­kets and the re­sur­gence...
19/06/2017
China Monthly TMT Up­date – June 2017
China pub­lishes new rules reg­u­lat­ing in­ter­net news ser­vices The Cy­ber­space Ad­min­is­tra­tion of China (“CAC”) pub­lished the Ad­min­is­trat­ive Pro­vi­sions on In­ter­net News Ser­vices (the “Pro­vi­sions”) on 2 May 2017.
10/03/2014
De­liv­er­ing Con­sumer Products ex­pert­ise in China
09/05/2017
China pub­lishes se­cur­ity re­view meas­ures for net­work products and...
The Cy­ber­space Ad­min­is­tra­tion of China (“CAC”) pub­lished the Se­cur­ity Re­view Meas­ures for Net­work Products and Ser­vices (Tri­al) (the “Meas­ures”) on 2 May 2017. This is only two months after the peri­od dur­ing which the pub­lic could provide com­ments on the first.
02/09/2013
In Sci­ence, In Sight: Com­puls­ory phar­ma­ceut­ic­al li­cences...
28/04/2017
European IP Snap­shot – April 2017 欧洲知产快讯 – 2017年四月
Bring­ing you reg­u­lar news of key de­vel­op­ments in European in­tel­lec­tu­al prop­erty law. 持续为您提供欧洲知识产权法律的关键更新。 COPY­RIGHT 著作权 Foot­ball As­so­ci­ation Premi­er League Ltd v Brit­ish Tele­com­mu­nic­a­tions Plc and oth­ers [2017] EWHC 480 (Ch) 英国超级足球联赛 诉 英国电信公司及其他[2017] EWHC.
02/09/2013
In Sci­ence, In Sight: Chin­a's Na­tion­al De­vel­op­ment...
28/04/2017
China Lifes­ci­ences Monthly Up­date – April 2017
Second round of drug price ne­go­ti­ation starts, 14 April The Min­istry of Hu­man Re­source and So­cial Se­cur­ity (the “HRSS”) re­leased the List of Drugs to be Ne­go­ti­ated for the Na­tion­al Drug Cata­logue for the Ba­sic Med­ic­al In­sur­ance, Work-re­lated In­jury In­sur­ance.
28/04/2017
China Quarterly IP Up­date - Janu­ary-March 2017
Bring­ing you reg­u­lar news of key de­vel­op­ments in the area of In­tel­lec­tu­al Prop­erty in China. Gen­er­al The Gen­er­al Rules of the Civil Law of the People’s Re­pub­lic of China provide fur­ther cla­ri­fic­a­tion on the ob­jects pro­tec­ted by in­tel­lec­tu­al prop­erty rights,.
25/04/2017
China Monthly TMC Up­date – April 2017
MIIT pro­poses changes to the ad­min­is­tra­tion of tele­com ser­vice li­cens­ing The Min­istry of In­dustry and In­form­a­tion Tech­no­logy ("MIIT") pub­lished the draft re­vi­sions to the Ad­min­is­trat­ive Meas­ures for Tele­com Ser­vice Li­cens­ing (the “Draft Re­vi­sions”) on 11 April.
14/04/2017
China pub­lishes draft meas­ures reg­u­lat­ing cross-bor­der trans­fer of...
The Cy­ber­space Ad­min­is­tra­tion of China ("CAC") pub­lished the Draft As­sess­ment Meas­ures for Trans­fer­ring Per­son­al Data and Im­port­ant Data to Over­seas Coun­tries (the "Draft") on 11 April 2017 to so­li­cit pub­lic opin­ions.
07/04/2017
Sev­en new Free Trade Zones have opened in China
An of­fi­cial state­ment re­leased on 31 March 2017 an­nounced that the State Coun­cil had ap­proved sev­en new Free Trade Zones (“FTZs”) in the provinces of Liaon­ing, Zheji­ang, Hen­an, Hubei, Sichuan, Shaanxi and Chongqing Mu­ni­cip­al­ity.
31/03/2017
After 30 years China over­hauls its civil law
Fol­low­ing the ex­am­in­a­tion of three draft ver­sions of the Gen­er­al Rules of the Civil Law of the People’s Re­pub­lic of China (“the Rules”), the fi­nal ver­sion of the Rules has been ad­op­ted at the Fifth Ses­sion of the 12th Na­tion­al People's Con­gress of the People's.
30/03/2017
Chinese Or­ange Book re­gime is likely to be es­tab­lished
The China Food and Drug Ad­min­is­tra­tion (“CF­DA”) held a meet­ing on 23 March 2017 to re­view the pro­cess of the re­form of the drug re­gis­tra­tion re­gime (the “Re­form”). The meet­ing sum­mar­ised the achieve­ments in 2016 and de­cided key tasks for the Re­form in the com­ing.